Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an update.
Neuren Pharmaceuticals has appointed Daryl DeKarske as Chief Regulatory Officer, bringing his extensive experience in global regulatory strategy and orphan drug indications to the company. This strategic addition is expected to significantly aid Neuren’s efforts in advancing NNZ-2591 for global markets, particularly in the Phase 3 program for Phelan-McDermid syndrome, thereby strengthening its position in the field of neurological disorder treatments.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is a company focused on developing new drug therapies for serious neurological disorders that emerge in early childhood, with a particular emphasis on conditions that have no or limited approved treatment options. The company has received orphan drug designation in the United States for its programs, which include DAYBUE™ (trofinetide) approved for Rett syndrome and NNZ-2591 in development for multiple neurodevelopmental disorders.
YTD Price Performance: -6.57%
Average Trading Volume: 1,250
Technical Sentiment Signal: Hold
Current Market Cap: $956.5M
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.